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================================================

Solute carrier (SLC) transporters are increasingly recognized as essential for ion, molecule, and other solute transport to support lysosomal function. To date, more than 30 lysosomal SLC transporters have been genetically identified, molecularly characterized, and investigated for a role in health and disease. Despite these advances, there remain lysosomal transport systems for which the molecular identity is obscure, and, conversely, orphan lysosomal SLC transporters with functional relevance unresolved. As the scope of lysosomal SLC transporters is broad, expression, functional characteristics, and disease associations for known family members are summarized in **Table** [1](#cpt450-tbl-0001){ref-type="table-wrap"}. Instead, we focus on recent discoveries in the lysosomal SLC transporter field that provide novel mechanistic insight into autophagy, phagocytosis, and exocytosis processes (**Figure** [1](#cpt450-fig-0001){ref-type="fig"}).
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Major lysosomal solute carrier transporters

  Gene name    Protein name   Substrate                                                                  Km                                                                                                                                                                                                                    Localization                                        Tissue with high expression                                 Cellular function                                                                                                            Associated diseases                          References (Pubmed ID)
  ------------ -------------- -------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- --------------------------------------------------------------------
  *SLC1A2*     EAAT2          [l]{.smallcaps}‐glutamate, [l]{.smallcaps} and [d]{.smallcaps}‐aspartate   52.7 ± 7.5 μM for [l]{.smallcaps}‐glutamate                                                                                                                                                                           Plasma membrane, Endo‐lysosomes                     Brain (Astrocytes)                                          Maintains glutamate clearance for synaptic function                                                                          Schizophrenia                                9539131 (1998); 10602327 (1999); 25064045 (2015)
  *SLC2A8*     GLUT8          [d]{.smallcaps}‐Glucose, [d]{.smallcaps}‐Fructose                          2 mM for Glucose                                                                                                                                                                                                      Endo‐Lysosomes, Endoplasmic Reticulum               Testes, Brain, Liver, Lung                                  Regulates facilitative glucose transport                                                                                     ‐                                            10821868 (2000); 19523115 (2009); 22822162 (2012)
  *SLC7A14*    CAT            Cationic [l]{.smallcaps}‐amino acids                                       1.9 ± 0.2 μM for Arginine                                                                                                                                                                                             Lysosomes, Plasma membrane                          Brain (mRNA expression)                                     Mediates lysosomal uptake of cationic amino acids                                                                            Autosomal Recessive Retinitis Pigmentosa     22787143 (2012); 24670872 (2014)
  *SLC9A6*     NHE6           Na^+^/H^+^ (Exchanger)                                                     5 to 50 mM for Na^+^                                                                                                                                                                                                  Endosomes, Mitochondria                             Brain, Skeletal muscle, heart                               Maintains pH homeostasis in organelles                                                                                       Angelman Syndrome and Christianson Subtype   9507001 (1998); 11940519 (2002); 26515654 (2016)
  *SLC11A1*    NRAMP1         Mn^2+^, Fe^2+^ other divalent ions                                         4 μM for Fe^2+^                                                                                                                                                                                                       Phagolysosomes                                      Macrophages, Neutrophils                                    Regulates iron homeostasis and host resistance to certain pathogens                                                          Mycobacterium Tuberculosis                   7964458 (1994); 19500110 (2009); 26353180 (2015)
  *SLC11A2*    DMT1           Fe^2+^,Cd^2+^,Co^2+^,Cu^2+^, Mn^2+^, Ni^2+^,Pb^2+^, Zn^2+^                 3 μM for Fe^2+^; 1 μM for Mn^2+^; 1 μM for Cd^2+^                                                                                                                                                                     Endo‐Lysosomes, Plasma membrane                     Ubiquitous, Duodenal enterocytes, Erythroid cells, Kidney   Mediates iron transport from endosomes to cytosol of duodenal enterocytes                                                    Microcytic Anemia                            16737442 (2006); 22313374 (2012)
  *Slc12A9*    CIP1           Cation Cl^‐^ (cotransporter)                                               ‐                                                                                                                                                                                                                     Lysosomes, Plasma membrane                          Ubiquitous                                                  Regulates intracellular chloride concentration                                                                               Bartter disease                              10871601 (2000); 23325410 (2013); 24802699 (2014)
  *SLC15A3*    PHT2           Di and Tripeptides, Histidine                                              1.3 ± 0.5 μM for dipeptides, 43 μM for Histidine                                                                                                                                                                      Endo‐Lysosomes, Vesicles                            Intestine, Spleen, Lung, Thymus                             Transports histidine and oligopeptides from inside the lysosome to the cytosol                                               ‐                                            11741232 (2000); 24695226 (2014); 24754256 (2014)
  *SLC15A4*    PHT1           Di and Tripeptides, Histidine                                              17 μM for Histidine                                                                                                                                                                                                   Endo‐Lysosomes, Vesicles                            Intestine, Eye, Brain                                       Transports histidine and oligopeptides from inside the lysosome to the cytosol                                               SLE                                          9092568 (1997); 25238095 (2014); 25310967 (2015)
  *SLC16A12*   MCT12          Monocarboxylic Acid, Creatine                                              567.4 μM for Creatine                                                                                                                                                                                                 Plasma membrane, Vesicles                           Retina, Lung, Kidney, Testes                                Transports monocarboxylic acids and creatine                                                                                 Cataract and Glucosuria                      18304496 (2008); 23578822 (2013)
  *SLC17A5*    Sialin         Sialic Acid, [l]{.smallcaps}‐Aspartate, [l]{.smallcaps}‐Glutamate          4 ± 2 mM for N‐acetyle Neuraminic acid; 5 ± 2mM for Glucoronic acid                                                                                                                                                   Lysosomes, Plasma membrane                          Ubiquitous                                                  Transports sialic acid and glucoronic acid out of lysosomes                                                                  Salla Disease                                10581036 (1999); 20424173 (2010); 23889254 (2013); 23900835 (2014)
  *SLC17A9*    VNUT           Purine Nucleotides                                                         0.61mM for ATP                                                                                                                                                                                                        Lysosomes, Secretory Vesicles                       Brain (Neurons), Adrenal, Thyroid                           Regulates vesicular ATP storage and exocytosis                                                                               Prokeratosis8                                22052906 (2008); 18375752 (2008); 25596766 (2015)
  *SLC26A11*   KBAT           HCO~3~ ^‐^,Cl^‐^,So~4~ ^‐^                                                 ‐                                                                                                                                                                                                                     Lysosomes, Plasma membrane                          Endothelial cells, Renal cells, Brain                       Regulates intracellular electrolyte balance                                                                                  Chronic Myeloid Leukemia                     12626430 (2003); 17002596 (2007); 25910210 (2015)
  *SLC29A3*    ENT3           Nucleosides                                                                1.9 ± 0.3 mM for Adenosine; 2.0 ± 0.4mM for Uridine                                                                                                                                                                   Endo‐Lysosomes                                      Ubiquitous                                                  Mediates nucleoside efflux across lysosome membrane                                                                          H Syndrome; PHID; Rosai Dorfman disease      15701636 (2005); 20595384 (2010); 22174130 (2012); 24535606 (2014)
  *SLC30A2*    ZnT2           Zn^2+^                                                                     14‐16 μM for Zn^2+^                                                                                                                                                                                                   Vesicles, Lysosomes, Plasma membrane                Breast, Pancreas, Kidney, Testis, Small intestine           Functions to secrete zinc into breast milk                                                                                   Acrodermatitis Enteropathica                 8617223 (1996); 9655614 (1998); 24456035 (2014)
  *SLC31A1*    CTR1           Cu^2+^                                                                     3.6 ± 0.8 μM for Copper                                                                                                                                                                                               Endo‐Lysosomes                                      Ubiquitous (mRNA expression)                                Facilitates copper transport in late endosomes and lysosomes                                                                 Wilson disease                               26945057 (2016); 12034741 (2002); 9207117 (1997)
  *SLC31A2*    CTR2           Cu^2+^                                                                     11.0 ± 2.5 μM for Copper                                                                                                                                                                                              Plasma membrane, Endosomes                          Gastro‐intestinal Tract, Ubiquitous                         Mediates low affinity copper uptake                                                                                          ‐                                            17617060 (2007); 24522273 (2014)
  *SLC32A1*    VIAAT          GABA, [l]{.smallcaps}‐Glycine                                              0.8 mM for GABA; 2.8 mM for Glycine                                                                                                                                                                                   Vesicles                                            CNS tissues                                                 Mediates GABA and glycine uptake in synaptic vesicles                                                                        Hyperexcitability Disorders                  12115694 (2002); 19843525 (2009); 25749864 (2015)
  *SLC36A1*    PAT1/LYAAT1    Glycine, Alanine, Proline, Serine, Alanine, GABA                           7.0 ± 0.7 mM for Glycine; 7.5 ± 0.6 mM for [l]{.smallcaps}‐Alanine; 2.8 ± 0.1 mM for [l]{.smallcaps}‐Proline; 69 ± 5 mM for [l]{.smallcaps}‐Serine; 6.3 ± 0.7 mM for [d]{.smallcaps}‐Alanine; 3.1 ± 0.2 mM for GABA   Lysosomes, Plasma membrane, Endoplasmic Reticulum   Brain, Intestine, Kidney, Spleen                            Transports small amino acids [l]{.smallcaps}‐Glycine, [l]{.smallcaps}‐Alanine and [l]{.smallcaps}‐Proline across lysosomes   Iminoglycinuria Digenic                      12893527 (2003); 16373326 (2005); 25880931 (2015)
  *SLC37A2*    SPX2           Glucose‐6‐Phosphate (G6P)                                                  ‐                                                                                                                                                                                                                     Plasma membrane, Endoplasmic Reticulum              Ubiquitous                                                  Functions as phosphate‐linked G6p antiporter                                                                                 ‐                                            17356011 (2007); 21949678 (2011)
  *SLC38A7*    SNAT7          Neutral [l]{.smallcaps}‐Amino acids                                        ‐                                                                                                                                                                                                                     Endo‐lysosomes                                      Brain, Liver, Muscle Uterus                                 Regulates [l]{.smallcaps}‐glutamine transport in neurons                                                                     ‐                                            18418736 (2008); 21511949 (2011)
  *SLC38A9*                   Low Capacity neutral [l]{.smallcaps}‐Amino acid transporter                39mM for Arginine                                                                                                                                                                                                     Lysosomes, Late endosomes                           Ubiquitous                                                  Acts as a sensor for [l]{.smallcaps}‐arginine in lysosomes                                                                   Upregulated in Lung Cancer                   25567906 (2015); 25963655 (2015); 25561175 (2015)
  *SLC39A8*    ZIP8           Zn^2+^                                                                     0.3 μM for Zn^2+^; 0.5 μM for Cd^2+^                                                                                                                                                                                  Vesicles, Plasma membrane                           Ubiquitous                                                  Regulates zinc influx                                                                                                        ‐                                            18270315 (2008); 26637978 (2015)
  *SLC40A1*    FPN1           Fe^2+^                                                                     ‐                                                                                                                                                                                                                     Lysosomes, Plasma membrane                          Macrophages, Liver, Duodenum,                               Mediates iron export from duodenal epithelial cells                                                                          Hemochromatosis                              10693807 (2000); 15114483 (2004); 24304836 (2014); 26059880 (2015)
  *SLC45A2*    MATP           Uncharacterized, transports substances for melanin synthesis               ‐                                                                                                                                                                                                                     Melanosomes, Plasma membrane                        Melanocytes, Skin, Eye                                      Regulates melanosome Ph                                                                                                      Oculocutaneous Albinism Type IV              26016411 (2015); 26057890 (2015)
  *SLC46A3*    FKSG16         Uncharacterized                                                            ‐                                                                                                                                                                                                                     Lysosomes, Plasma membrane                          Kidney, Liver, Placenta                                     Mediates antibody drug conjugate‐ maytansine efflux from lysosomes                                                           ‐                                            26631267 (2015)
  *SLC48A1*    HRG‐1          Heme                                                                       125 μM                                                                                                                                                                                                                Endo‐Lysosomes                                      Liver, Heart, Muscle, Small Intestine                       Regulates intracellular heme availability through endo‐lysosomal compartment                                                 ‐                                            16143108 (2005); 18418376 (2008); 23395172 (2013)

CAT1, cationic amino acid transporter 1; CIP1, cation‐chloride cotransporter‐interacting protein 1; CTR2, copper transporter 2; DMT1, divalent metal transporter 1; EAAT2, excitatory amino‐acid transporter 2; ENT3, equilibrative nucleoside transporter; FPN1, ferroportin1; Glut8, glucose transporter 8; HRG‐1, heme‐responsive gene 1; KBAT, kidney brain anion transporter; K~m~, apparent substrate affinity LYAAT1, lysosomal amino acid transporter 1; MATP, membrane‐associated transporter protein; MCT12, monocarboxylate transporter 12; NHE6, sodium hydrogen exchanger; NRAMP1, natural resistance‐associated macrophage protein 1; PAT1, proton/amino acid transporter 1; PHT1, peptide histidine transporter 1; PHT2, peptide histidine transporter 2; SNAT7, sodium‐coupled neutral amino acid transporter 7; SPX2, sugar phosphate exchanger 2; URLC11, upregulated in lung cancer 11; VIAAT, vesicular inhibitory amino acid transporter; VNUT, vesicular nucleotide transporter; ZIP8, zinc transporter 8; ZnT2, zinc transporter 2.

![A schematic model of the lysosomal solute carrier (SLC)ome: emerging roles in cellular pathophysiology and pharmacology. A multitude of lysosomal SLCs across lysosomal membrane is involved in the lysosomal transport of solutes. Significant advances in understanding the lysosome proteome has revealed novel roles for lysosomal SLCs, including SLC38A9 as an amino acid sensor (by direct interaction with mTOR complex), SLC17A9 as a mediator of adenosine triphosphate (ATP) exocytosis, SLC15A3/A4 as a participant in toll‐like receptor (TLR) signaling, SLC29A3 as a regulator of nucleoside salvage, and SLC46A3 as a facilitator of antibody‐drug conjugate maytansine efflux. mTOR, mammalian target of Rapamycin; RagA, Ragulator A; RagC, Ragulator C.](CPT-100-431-g001){#cpt450-fig-0001}

Distinct amino acid transport systems exist in the lysosomal membrane to transit cystine, cysteine, cationic amino acids, dicarboxylic amino acids, and small and large neutral amino acids, as elucidated over the last 3 decades. Similarly, the process of autophagy -- lysosomal degradation of defective intracellular material during cellular stress -- was recognized well over 3 decades ago. Yet, the mechanism for precisely relaying cellular nutrient status to lysosomes to regulate the autophagy process was unclear. Previous work predicted that the species and quantity of amino acids inside the lysosomal lumen were somehow sensed by the lysosome to allow docking of a master regulator of autophagy (mammalian target of rapamycin complex 1 \[mTORC1\]) to the lysosomal surface to initiate an autophagy signal. However, this putative lysosomal nutrient sensor for mTORC1 remained unresolved. Three groups have now independently discovered SLC38A9 as an arginine sensor at the lysosomal membrane, identifying a central role for this transporter in regulating the steps preceding autophagy.

SLC38A9 is an 11‐pass lysosomal transmembrane protein and a low capacity neutral amino acid transporter that directly interacts with Ragulator--Ragulator GTPases conveying the nutrient status of the cell to the mTORC1 complex.[1](#cpt450-bib-0001){ref-type="ref"} The initiation and formation of double‐membraned autophagosomes tightly links mTORC1 regulation to this nutrient‐sensing mechanism. Thus, identification of SLC38A9 as an amino acid sensor was a critical step to understanding lysosomal signaling processes in autophagy. It is not yet known whether additional amino acid sensors or analogous sensors for sugars, lipids, or nucleotides exist within or outside lysosomes, but these discoveries drive the quest to find new sensors for autophagy initiation and termination. Moreover, modulation of lysosomal SLC38A9 transporters may offer a new therapeutic intervention in neurodegenerative and aging disorders in which autophagy is perturbed.

Lysosomes also serve as the terminal compartment for cellular endocytic machinery and degradation of endocytosed material. Besides other functions, phagocytosis is essential for internalizing pathogens for degradation and for orchestrating immune responses. The handling of pathogens by dendritic cells for the engagement of adaptive immune response is intricately tied to endolysosomal function. Among lysosomal SLC transporters known to facilitate this process, the endolysosomal peptide transporters, SLC15A3 and SLC15A4, in dendritic cells are reported to mediate the intracellular sensing of pathogens after toll‐like receptor stimulation.[2](#cpt450-bib-0002){ref-type="ref"} Both transporters assist in the egress of bacterially derived components, particularly muramyl dipeptide, to facilitate the NOD2‐mediated immune response. Consistently, single nucleotide polymorphism of SLC15A4 is found to associate with autoimmune disease systemic lupus erythematosus. Similarly, SLC11A1 (formerly *Nramp1*), a divalent metal transporter, is reported in dynamic host‐pathogen interactions essential for conferring resistance to certain pathogens. Mutations in SLC11A1 associate with infectious (e.g., tuberculosis, leprosy) and inflammatory (e.g., rheumatoid arthritis) diseases.

Recently, the role of an acidic pH‐dependent lysosomal nucleoside transporter, SLC29A3, has been linked to macrophage phagocytic function.[3](#cpt450-bib-0003){ref-type="ref"} SLC29A3 is predicted to salvage lysosomal nucleobases, nucleosides, and nucleotides, presumably derived from encapsulated pathogens and host macrophage‐derived nucleic acids. Accumulating evidence reveals that SLC29A3 mutations can cause a spectrum of human genetic disorders due to abnormal lysosomal nucleoside buildup and increased intralysosomal pH. These diseases include: H syndrome (progressive scleroderma, hyperpigmentation, hypertrichosis, facial telangiectases and dermal and subcutaneous fibrosis); pigmented hypertrichotic dermatosis and insulin‐dependent diabetes syndrome; familial Rosai‐Dorfman disease; familial histiocytosis; and sinus histiocytosis with massive lymphadenopathy. SLC29A3 spectrum disorders are allelic, share common mutation(s), and share overlapping manifestations that display an intriguing resemblance to lysosomal storage disorders. Although the basis of these monogenic disorders is only beginning to be appreciated, further studies on the involvement of SLC29A3 in lysosomal and cellular homeostasis should clarify the role of macrophages and other cell types in the pathogenesis of SLC29A3 spectrum disorders.

The lysosome participates in membrane trafficking and exocytosis, wherein the lysosome expels its cargo outside the cell. Lysosomal exocytosis is also important in plasma membrane repair and cholesterol homeostasis. Deficiency of lysosomal proteins in Niemann--Pick type C1 disease or Niemann--Pick type C2 diminish cholesterol efflux from the lysosomal compartment, leading to abnormal lysosomal cholesterol accumulation. Correspondingly, a recent finding identified SLC17A9 in lysosome‐mediated adenosine triphosphate (ATP) release.[4](#cpt450-bib-0004){ref-type="ref"} Because ATP is an important neurotransmitter, lysosomal exocytosis maintains regulated ATP release from neurons and/or astrocytes. This lysosomal ATP release is essential as a perturbation of SLC17A9 significantly affected neurotransmission. ATP facilitates synaptic efficiency and plasticity in neurons, and its dysregulation associates with central nervous system pathologies, including brain ischemia, inflammation, and stroke.

POTENTIAL THERAPEUTIC APPROACHES TARGETING LYSOSOMAL SLC TRANSPORTERS {#cpt450-sec-0002}
=====================================================================

The localization of SLC transporters on the lysosomal membrane represents a potential class of "druggable" targets for treating lysosomal disorders. However, success, to date, is limited due to the initial requirement of endocytosis for drugs to reach the lysosome. The absence of an SLC transporter crystal structure also slows the drug discovery process. Nevertheless, alternative strategies to effectively utilize or target lysosomal SLCs for development of improved therapeutics are underway. For instance, antibody‐drug conjugates are emerging as a cancer‐specific treatment to avoid off‐target toxicities observed with conventional chemotherapeutic agents.

Upon binding of antibody‐drug conjugates to surface antigens on cancer cells, they are endocytosed and accumulate in lysosomes. The antibody component is catabolized in the lysosome‐generating active drug. However, the active drug now faces the impending challenge of finding its way out of the lysosome to reach its target site (nucleus, cytoplasm, cytoskeleton, etc.) for action. Because oligonucleotide (siRNA, miRNA) therapeutics and nanoparticle‐based therapeutics face the same drug‐exit impediment, lysosomal accumulation and degradation have become a widespread concern.

Cleavable linker technology, proton‐sponge effect, ion pair formation, and hydrophobic modification of vectors or cargos are some of the techniques being currently used for effective drug delivery. In some cases, such strategies are harmful, disrupting (endo) lysosomal membranes. In this regard, lysosomal SLCs offer great promise to aid safe efflux of therapeutic cargos from lysosomes. A recent discovery of SLC46A3 facilitating transport of a noncleavable antibody‐drug conjugate catabolite to export cargo from the lysosome validates the feasibility of this strategy.[5](#cpt450-bib-0005){ref-type="ref"} Identification and characterization of orphan SLC46A3 identified maytansine as a substrate for SLC46A3, further clarifying the mechanism of noncleavable maytansine‐based antibody drug conjugates, including ado‐trastuzumab emtansine. The discovery of SLC46A3 as a means for antibody‐drug conjugates to target cancer cells suggests future investigation will identify other lysosomal SLC transporters with substrates amenable to therapeutic conjugation for lysosomal exit. In another example, SLC31A2, the lysosomal copper transporter, regulates sensitivity to cisplatin treatment. Measurement of copper flux with new intracellular copper sensors enables testing for copper‐dependent sensitivity to chemotherapeutic agents.

Enhancement of transporter activity is a treatment option for diseases with loss of transporter function. The lysosomal glutamate transporter, SLC1A2 (EAAT2), is involved in glutamate clearance in astroglial cells, and its protein expression decreases in neurological disorders, like Alzheimer disease, amyotrophic lateral sclerosis, and schizophrenia. The antibiotic ceftriaxone increases transcription of SLC1A2 through modulating nuclear factor‐kappa B signaling and riluzole, an amyotrophic lateral sclerosis therapeutic, reportedly increases transport activity of SLC1A1 and SLC1A2, supporting this strategy. Furthermore, SLC12A9 is a member of the sodium chloride cotransporter family (SLC12) that regulates ion gradients across renal tubules and maintains cell volume. Mutations in SLC12A9 associate with Bartter disease, characterized by a defect in the thick ascending limb of the loop of Henle, hypokalemia, and alkalosis. Diuretic drugs, like bumetanide and furosemide, inhibit multiple SLC12 transporters; thus, directed development of novel diuretics that target specific SLC12 transporters may offer more effective disease management.

Finally, various lysosomal storage disorders are caused by an aberrant accumulation of undigested material within lysosomes. Classic examples involving lysosomal transporters include SLC17A5 and MFSD8 in Salla disease and neuronal ceroid lipofuscinosis, respectively. Although there are no curative treatments yet, enzyme replacement therapy and gene therapy are promising options. Some treatment options for lysosomal storage disorders, like Niemen‐Pick disease, Gaucher disease, and alpha‐mannosidosis using enzyme replacement therapy are already approved or are under active (pre)clinical evaluations.

Overall, targeting and utilization of SLC transporters for better treatment and management of lysosomal disorders or drug delivery is becoming a reality and research on lysosomal SLCs is gaining momentum to realize new therapeutic possibilities.
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